Eris Lifesciences Ltd.

s is a chronic‑focused branded‑generics company in cardio‑metabolic and related therapies. It operates with a pure‑India, high‑margin, specialty model. Acquisitions in derma/endocrine expand its therapy coverage. Risks are doctor‑coverage saturation and pricing pressure from larger chronic players.